1-Aminoindanes as novel motif with potential atypical antipsychotic properties

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 489-493

  Graham, James M ^a   Coughenour, Linda L ^a   Barr, Bridget M ^a   Rock, David L ^a   Nikam, Sham S ^a  

^a PFIZER INC   (United States)

Author keywords

5HT antagonism; Atypical antipsychotic; D2 antagonism; hERG; Indane

Indexed keywords

1 AMINOINDAN DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOFETILIDE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; INDAN DERIVATIVE; KETANSERIN; NEUROLEPTIC AGENT; OXINDOLE; PRAZOSIN; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; BINDING AFFINITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; MOOD DISORDER; PSYCHOSIS; SCHIZOPHRENIA; SEQUENCE HOMOLOGY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ANTIPSYCHOTIC AGENTS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INDANS; MOLECULAR STRUCTURE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2;

EID: 38149006973     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.106     Document Type: Article

References (21)

1. World Health Organization. WHO Fact Sheet Number 265; The World Health Organization: Geneva, Switzerland, 2001.
2. Capuano B., Crosby I.T., and Lloyd E. J. Curr. Med. Chem. 9 (2002) 521
3. Seeman P., Chau-Wong M., Tedesco J., and Wong K. Nature 261 (1976) 717
4. Martin, A. R. In Burger's Medicinal Chemistry and Drug Discovery, 5th ed.; Wolf, M. E., Ed.; Wiley-Interscience: New York, 1997; Vol. 5, p. 195.
5. Meltzer H.Y., Matsubara S., and Lee J. J. Pharm. Exp. Ther. 251 (1989) 238
6. Cunningham Owens D.G. Drugs 51 (1996) 895
7. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M., Goldstein D., Pashdag M.A., Mintz J., and Marder S. J. Clin. Psychiatry 60 (1999) 358
8. Roth B.D., Sheffler D.J., and Kroeze W.K. Nature Rev. 3 (2004) 353
9. Cunningham Owens D.G. Drugs 51 (1996) 895
10. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M., Goldstein D., Pashdag M.A., Mintz J., and Marder S. J. Clin. Psychiatry 60 (1999) 358
11. Green B. Curr. Med. Res. Opin. 15 (1999) 79
12. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. J. Prog. Neuro-Psychopharm. Biol. Psychiatry 27 (2003) 1159
13. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., Jayathilake K., and Meltzer H.Y. Am. J. Psychiatry 158 (2001) 1722
14. Svensson T.H. Prog. Neuro-Psychopharm. Biol. Psychiatry 27 (2003) 1145
15. Praxcik M.T., and Perez D.M. . J. Pharmacol. Exp. Ther. 298 (2001) 403
16. Brown A.M. Card. Saf. Noncard. Drugs (2005) 67
17. Sanguinetti M.C., and Tristani-Firouzi M. Nature 440 (2006) 463
18. Finlayson K., Pennington A.J., and Kelly J.S. Eur. J. Pharm. 412 (2001) 203
19. Ward K.J., and Gill J.S. Exp. Opin. Invest. Drugs 6 (1997) 1269
20. Greengrass, P. M.; Stewart, M.; Wood, C. M. WO2003021271.
21. i affinity constants using the Cheng-Prusoff equation.